XSAU
4013
Market cap24bUSD
Nov 12, Last price
264.00SAR
Name
Dr Sulaiman Al-Habib Medical Services Group Co
Chart & performance
P/E
38.48
P/S
6.74
EPS
6.86
Div yield, %
1.77%
Shrs. gr., 5y
—
Rev. gr., 5y
18.52%
Revenues
13.71b
+22.38%
Net income
2.40b
+3.72%
CFO
3.08b
+3.84%
Dividend
Aug 02, 20261.33 SAR/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Headquartered in Riyadh, Saudi Arabia, Dr. Sulaiman Al Habib Medical Services Group Company, established in 1993, specializes in the development, management, and operation of a wide spectrum of healthcare facilities across the Kingdom. Its extensive portfolio encompasses general and specialized hospitals, various medical complexes, outpatient surgical centers, and pharmaceutical facilities. The group operates hospitals focusing on specific areas such as maternity services, orthopedics, and spinal surgeries. Furthermore, it oversees specialized clinics for dermatology, plastic surgery, ophthalmology, obesity treatment, and fertility, complemented by its network of pharmacies. Beyond direct patient care, the company provides home medical services, advanced laboratory diagnostics, technology and information system support, facility upkeep, medical equipment maintenance, and telemedicine solutions.
Key people
Sulaiman Abdulaziz Al Habib
Non-Executive Chairman of the Board, Founder · since 2018
Faisal Abdullah Ali Al Nassar
Group Chief Executive Officer, Group Chief Financial Officer, Executive Director · since 2023
Abdulelah Abdulrahman Saleh Al Mayman
Chief Executive Officer and Member of the Board of Managers of Hulool Al Sahabah for IT & Communication Company · since 2021
Awad Abdullah Al Omari
Chief Medical Officer and Academic Affairs, Chief Executive Officer and Member of the Board of Managers of Rawabet Medical Company · since 2023
Abdulwahab Abdullah Mohammed Al Abdulwahab
Chief Operating Officer
Ahmed Mohammed Babatin
Chief People Officer · since 2024
Sulaiman Abdul Aziz Sulaiman Al Majed
Senior Vice President - Medical Affairs, Consultant of Internal and Chest Diseases and Supervisor of diagnostic radiology, laboratory and nursing · since 2022
Riyadh Muhammad Bajodah
Acting Vice President - Digital Business · since 2024
Mohamed Abdelmoula Shalaby
Vice President - Supply Chain · since 2024
Saud Abdulaziz Bin Mohammed Saleh Al Arifi
Group General Counsel, Secretary of the Board · since 2022
Riyad Saleh Abdulaziz Al Atiqi
General Director - Pharmaceutical Facilities, Member of the Board of Managers of Asharq Alawsat Pharmacies Company · since 2022
Hesham Sulaiman Abdulaziz Al Habib
Chief Business Development and Strategy Officer, Executive Director · since 2022
Abdullah Sulaiman Al Herbish
Senior Vice President - Physician Affairs and Consultant Pediatric Endocrinologist and Diabetologist, Executive Director · since 2024
Vimal Subramanian
Chief Internal Auditor · since 2022
Saleh Mohammed Abdulaziz Al Habib
Non-Executive Director · since 2018
Ibrahim Abdulaziz Al Jammaz
Independent Director · since 2024
Rasheed Abdulrahman Al Rasheed
Independent Director · since 2021
Non-Executive Independent Vice Chairman of the Board · since 2024
Abdulrahman Bin Suleiman Hmoud Al Taraigi
Independent Director · since 2018
Valuation
Title SAR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||